TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

Benzinga · 3d ago
TD Cowen analyst Yaron Werber upgrades Genmab (NASDAQ:GMAB) from Hold to Buy and raises the price target from $32 to $43.